[ad_1]
Nicola P. Klein
GlaxoSmithKline's measles, mumps and rubella vaccine has been shown to be safe and effective in healthy children in a phase III clinical trial.
The results of the study had already been presented to IDWeek and were published in the journal. Journal of the Society of Pediatric Infectious Diseases.
If the vaccine becomes available commercially in the United States, it will offer an option that is not inferior to the currently licensed MMR vaccine, researchers said.
Nicola P. Klein, MD, PhD, A senior researcher at Kaiser Permanente Northern California Research Division and director of the Kaiser Permanente Vaccine Center wrote that a single vaccine against measles, mumps and rubella – MMR II (Merck) – was available. United States
"We believe that if MMR-RIT (Priorix, GlaxoSmithKline) is licensed, this could be a valuable option for preventing measles, mumps and rubella in American children," Klein said. Infectious Diseases in Children. "In addition, this could also help reduce the potential risks of a vaccine shortage."
In the study, healthy children from Estonia, Finland, Mexico, Spain and the United States aged 12 to 15 months were randomized to receive a dose of MMR II, taken from one of three lots, or MMR-RIT in addition to all other drugs. Routine vaccinations recommended by age. Antibody concentrations and serological response rates of infants were examined 43 days after vaccination.
Klein and colleagues observed a "robust and non-inferior" immune response in infants vaccinated with RRO-RIT compared to those receiving MMR II, and the immunogenicity of the three lots of RRO-RIT was consistent, with researchers pointed out that almost all (more than 97% of infants had a serological response to MMR components.
Immune responses from other vaccines administered at the same time were similar in infants receiving MMR and MMR-RIT, and infants in both groups had similar reactogenicity profiles.
In addition, Klein and colleagues did not observe any safety concerns related to MMR-RIT vaccination.
Like RRO II, RRO-RIT is a live virus vaccine.
"These results suggest that the ROR-RIT could be a valid option for the prevention of measles, mumps and rubella in children in the United States and help ensure that the United States has a second MMR vaccine available in case of hypothetical shortage of MMR vaccine, "said Klein and his colleagues wrote. – by Katherine Bortz
Disclosures: Klein indicates that she has received grants from GlaxoSmithKline, Merck, Pfizer, Sanofi Pasteur, Novartis, Protein Science and MedImmune. Please consult the study for the relevant financial information of all other authors.
[ad_2]
Source link
